As it heads into the upfronts, the tech giant is leaning on the NFL, NBA, WNBA and other events to drive its ad business ...

The co-antibody therapy JNJ-4804 -- a fixed-dose combination of guselkumab (Tremfya) and golimumab (Simponi) -- showed clinically meaningful efficacy exceeding that of either drug alone in patients ...

A comparative analysis identifies the top IL-23 inhibitors that were least likely to be associated with the development of ...

BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...

A "top-down" approach of early aggressive therapy for Crohn's disease continued to achieve better outcomes versus a conventional accelerated "step-up" approach, long-term follow-up data from the ...

Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence suggests that biologic therapies may differentially influence the development ...

Phase 1 clinical trial of SL-325 enrollment complete; data expected in the second quarter of 2026 –Phase 2 clinical trial of SL-325 in patients ...

Researchers identify TNF driven injury pathways in brain death donors and test anti-TNF therapy to improve kidney graft ...

Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative ...

Allogeneic HSCT is frequently complicated by acute GVHD (~50%) and chronic GVHD (30%–70%), with steroid-refractory disease representing a major unmet need despite ruxolitinib availability. CK0802 ...

Researchers from the University of Messina found that cannabidiol (CBD) reduced inflammation in canine mammary carcinoma ...

Combination therapy with multiple biologics may be on the horizon for patients with psoriatic arthritis, according to a ...